Aytu BioPharma (AYTU) & Its Peers Head-To-Head Review

Aytu BioPharma (NASDAQ:AYTU) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Aytu BioPharma to similar companies based on the strength of its earnings, profitability, analyst recommendations, dividends, risk, institutional ownership and valuation.

Risk & Volatility

Aytu BioPharma has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500. Comparatively, Aytu BioPharma’s competitors have a beta of -3.81, suggesting that their average stock price is 481% less volatile than the S&P 500.

Profitability

This table compares Aytu BioPharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-24.76%	-56.54%	-13.14%
Aytu BioPharma Competitors	-2,379.48%	-219.92%	-15.47%

Institutional and Insider Ownership

33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 6.1% of Aytu BioPharma shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for Aytu BioPharma and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	2	0	2	0	2.00
Aytu BioPharma Competitors	7776	13772	25741	1037	2.41

Aytu BioPharma presently has a consensus price target of $14.50, suggesting a potential upside of 701.10%. As a group, “Pharmaceuticals” companies have a potential upside of 24.77%. Given Aytu BioPharma’s higher possible upside, equities research analysts plainly believe Aytu BioPharma is more favorable than its competitors.

Earnings & Valuation

This table compares Aytu BioPharma and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Aytu BioPharma	$57.57 million	-$14.25 million	-1.09
Aytu BioPharma Competitors	$4.34 billion	$3.17 billion	552.48

Aytu BioPharma’s competitors have higher revenue and earnings than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on commercializing prescription medicines and other healthcare products. The company’s portfolio has primarily centered on treatments for attention-deficit/hyperactivity disorder (ADHD), along with select pediatric and primary-care products. Aytu’s ADHD products have included Adzenys XR-ODT, an extended-release orally disintegrating tablet containing amphetamine; Cotempla XR-ODT, an extended-release orally disintegrating tablet containing methylphenidate; and Evekeo, an amphetamine sulfate product.